Advertisement

Drugs & Aging

, Volume 36, Issue 1, pp 29–37 | Cite as

Influenza Vaccination in Older Adults: Recent Innovations and Practical Applications

  • Melissa K. AndrewEmail author
  • Susan K. Bowles
  • Graham Pawelec
  • Laura Haynes
  • George A. Kuchel
  • Shelly A. McNeil
  • Janet E. McElhaney
Review Article
  • 148 Downloads

Abstract

Influenza can lead to serious illness, particularly for older adults. In addition to short-term morbidity and mortality during the acute infection, recovery can be prolonged and often incomplete. This may lead to persistent declines in health and function, including catastrophic disability, which has dramatic implications for the well-being and support needs of older adults and their caregivers. All of this means that prevention of infection and effective treatment when illness has occurred are of paramount importance. In this narrative review, we discuss the effectiveness of influenza vaccines for the prevention of influenza illness and serious outcomes in older adults. We review evidence of vaccine effectiveness for older adults in comparison with younger age groups, and also highlight the importance of frailty as a determinant of vaccine effectiveness. We then turn our attention to the question of why older and frailer individuals have poorer vaccine responses, and consider changes in immune function and inflammatory responses. This sets the stage for a discussion of newer influenza vaccine products that have been developed with the aim of enhancing vaccine effectiveness in older adults. We review the available evidence on vaccine efficacy, effectiveness and cost benefits, consider the potential place of these innovations in clinical geriatric practice, and discuss international advisory committee recommendations on influenza vaccination in older adults. Finally, we highlight the importance of influenza prevention to support healthy aging, along with the need to improve vaccine coverage rates using available vaccine products, and to spur development of better influenza vaccines for older adults in the near future.

Notes

Compliance with Ethical Standards

Conflict of interest

Melissa K. Andrew reports grant funding from GlaxoSmithKline (GSK), Pfizer, Sanofi, Canadian Institute of Health Research (CIHR), Public Health Agency of Canada (PHAC), and the Canadian Frailty Network; no personal financial conflicts of interest. Susan K. Bowles reports grant funding from the Dalhousie Pharmacy Endowment Fund; no financial conflicts of interest. Graham Pawelec reports no financial conflicts of interest. Laura Haynes reports grant funding from the National Institutes of Health (NIH; AG021600); no financial conflicts of interest. George A. Kuchel reports grant funding from the NIH (AG048023, AG021600, AI124297, AG052608, GM124922, AG056925), Patient-Centered Outcomes Research Institute (PCORI) and Novartis; no personal financial conflicts of interest. He is also supported by the Travelers Chair in Geriatrics and Gerontology. Shelly A. McNeil reports grants and payments from the GSK group of companies, Pfizer, Merck, Novartis, Sanofi, PHAC and CIHR. Janet E. McElhaney reports payments to her institution from GSK, Sanofi, and Pfizer, and is supported by the Health Sciences North Volunteer Association Research Chair in Healthy Aging.

Funding

None of the authors received any funding or payment for the preparation of this review.

References

  1. 1.
    Nichol KL. Influenza vaccination in the elderly: impact on hospitalisation and mortality. Drugs Aging. 2005;22(6):495–515.CrossRefGoogle Scholar
  2. 2.
    Iuliano AD, Roguski KM, Chang HH, Muscatello DJ, Palekar R, Tempia S, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. 2018;391(10127):1285–300.CrossRefGoogle Scholar
  3. 3.
    Nichols MK, Andrew MK, Hatchette TF, Ambrose A, Boivin G, Bowie W, et al. Influenza vaccine effectiveness to prevent influenza-related hospitalizations and serious outcomes in Canadian adults over the 2011/12 through 2013/14 influenza seasons: a pooled analysis from the Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance (SOS Network). Vaccine. 2018;36(16):2166–75.CrossRefGoogle Scholar
  4. 4.
    World Health Organization: Seasonal Influenza Fact Sheet 2018. http://www.who.int/mediacentre/factsheets/fs211/en/. Accessed 24 Oct 2018.
  5. 5.
    Centers for Disease Control and Prevention. Flu Vaccination Coverage, United States, 2016-17 Influenza Season. https://www.cdc.gov/flu/fluvaxview/coverage-1617estimates.htm. Accessed 24 Oct 2018.
  6. 6.
    Public Health Agency of Canada. 2016/17 seasonal influenza vaccine coverage in Canada. 2018. http://publications.gc.ca/collections/collection_2018/aspc-phac/HP40-198-2017-eng.pdf. Accessed 24 Oct 2018.
  7. 7.
    European Cenre for Disease Prevention and Control. Seasonal influenza vaccination in Europe—vaccination recommendations and coverage rates for eight influenza seasons (2007–2008 to 2014–2015). 2017. https://ecdc.europa.eu/en/publications-data/seasonal-influenza-vaccination-europe-vaccination-recommendations-and-coverage-2007-2015. Accessed 24 Oct 2018.
  8. 8.
    Karki S, Dyda A, Newall A, Heywood A, MacIntyre CR, McIntyre P, et al. Comparison of influenza vaccination coverage between immigrant and Australian-born adults. Vaccine. 2016;34(50):6388–95.CrossRefGoogle Scholar
  9. 9.
    Cheng AC, Dwyer DE, Holmes M, Irving LB, Brown SG, Waterer GW, et al. Influenza epidemiology, vaccine coverage and vaccine effectiveness in sentinel Australian hospitals in 2013: the influenza complications alert network. Commun Dis Intell Q Rep. 2014;38(2):E143–9.Google Scholar
  10. 10.
    Covinsky KE, Palmer RM, Fortinsky RH, Counsell SR, Stewart AL, Kresevic D, et al. Loss of independence in activities of daily living in older adults hospitalized with medical illnesses: increased vulnerability with age. J Am Geriatr Soc. 2003;51(4):451–8.CrossRefGoogle Scholar
  11. 11.
    Andrew MK, Lees C, Godin J, Black K, McElhaney J, et al. Frailty hinders recovery from acute respiratory illness in older adults [abstract]. In: ID Week: 4–8 Oct 2017; San Diego, CA.Google Scholar
  12. 12.
    Andrew MK, MacDonald S, Ye L, Ambrose A, et al., on behalf of the CIRN SOS Network Investigators and the TIBDN Investigators. Impact of frailty on influenza vaccine effectiveness and clinical outcomes: experience from the Canadian immunization research network (CIRN) Serious Outcomes Surveillance (SOS) Network 2011/12 Season [abstract]. In: 12th Canadian Immunization Conference, Ottawa, ON, 6–8 Dec 2016.Google Scholar
  13. 13.
    Andrew MK, Gilca V, Waite N, Pereira JA. Examining the knowledge, attitudes and experiences of canadian seniors towards influenza (the EXACT survey) [abstract]. In: Canadian immunization conference, Ottawa, ON, 4–6 Dec 2018.Google Scholar
  14. 14.
    Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. Lancet. 2013;381(9868):752–62.CrossRefGoogle Scholar
  15. 15.
    Andrew MK, Shinde V, Ye L, Hatchette T, Haguinet F, Dos Santos G, et al. The importance of frailty in the assessment of influenza vaccine effectiveness against influenza-related hospitalization in elderly people. J Infect Dis. 2017;216(4):405–14.CrossRefGoogle Scholar
  16. 16.
    Weinberg GA, Szilagyi PG. Vaccine epidemiology: efficacy, effectiveness, and the translational research roadmap. J Infect Dis. 2010;201(11):1607–10.CrossRefGoogle Scholar
  17. 17.
    van Doorn E, Darvishian M, Dijkstra F, Donker GA, Overduin P, Meijer A, et al. Influenza vaccine effectiveness estimates in the Dutch population from 2003 to 2014: the test-negative design case-control study with different control groups. Vaccine. 2017;35(21):2831–9.CrossRefGoogle Scholar
  18. 18.
    Cowling BJ, Feng S, Finelli L, Steffens A, Fowlkes A. Assessment of influenza vaccine effectiveness in a sentinel surveillance network 2010-13, United States. Vaccine. 2016;34(1):61–6.CrossRefGoogle Scholar
  19. 19.
    Skowronski DM, Chambers C, De Serres G, Sabaiduc S, Winter AL, Dickinson JA, et al. Age-related differences in influenza b infection by lineage in a community-based sentinel system, 2010-2011 to 2015-2016, Canada. J Infect Dis. 2017;216(6):697–702.CrossRefGoogle Scholar
  20. 20.
    Cohen JM, Silva ML, Caini S, Ciblak M, Mosnier A, Daviaud I, et al. Striking similarities in the presentation and duration of illness of influenza A and B in the community: a study based on sentinel surveillance networks in France and Turkey, 2010-2012. PLoS One. 2015;10(10):e0139431.CrossRefGoogle Scholar
  21. 21.
    Gianino MM, Politano G, Scarmozzino A, Charrier L, Testa M, Giacomelli S, et al. Estimation of sickness absenteeism among Italian healthcare workers during seasonal influenza epidemics. PLoS One. 2017;12(8):e0182510.CrossRefGoogle Scholar
  22. 22.
    Jackson ML, Phillips CH, Benoit J, Jackson LA, Gaglani M, Murthy K, et al. Burden of medically attended influenza infection and cases averted by vaccination—United States, 2013/14 through 2015/16 influenza seasons. Vaccine. 2018;36(4):467–72.CrossRefGoogle Scholar
  23. 23.
    Van Wormer JJ, King JP, Gajewski A, McLean HQ, Belongia EA. Influenza and workplace productivity loss in working adults. J Occup Environ Med. 2017;59(12):1135–9.CrossRefGoogle Scholar
  24. 24.
    El Omeiri N, Azziz-Baumgartner E, Thompson MG, REVELAC-i network participants, Clara W, Cerpa M, et al. Seasonal influenza vaccine effectiveness against laboratory-confirmed influenza hospitalizations - Latin America, 2013. Vaccine. 2018;36(24):3555–66.CrossRefGoogle Scholar
  25. 25.
    Andrew MK, Shinde V, Hatchette T, Ambrose A, Boivin G, Bowie W, et al. Influenza vaccine effectiveness against influenza-related hospitalization during a season with mixed outbreaks of four influenza viruses: a test-negative case-control study in adults in Canada. BMC Infect Dis. 2017;17(1):805.CrossRefGoogle Scholar
  26. 26.
    Petrie JG, Ohmit SE, Cheng CK, Martin ET, Malosh RE, Lauring AS, et al. Influenza vaccine effectiveness against antigenically drifted influenza higher than expected in hospitalized adults: 2014-2015. Clin Infect Dis. 2016;63(8):1017–25.CrossRefGoogle Scholar
  27. 27.
    Kissling E, Rondy M, I-MOVE/I-MOVE+ study team. Early 2016/17 vaccine effectiveness estimates against influenza A(H3N2): I-MOVE multicentre case control studies at primary care and hospital levels in Europe. Eur Surveill. 2017.  https://doi.org/10.2807/1560-7917.ES.2017.22.7.30464.Google Scholar
  28. 28.
    Sridhar S, Begom S, Bermingham A, Hoschler K, Adamson W, Carman W, et al. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat Med. 2013;19(10):1305–12.CrossRefGoogle Scholar
  29. 29.
    Rondy M, El Omeiri N, Thompson MG, Leveque A, Moren A, Sullivan SG. Effectiveness of influenza vaccines in preventing severe influenza illness among adults: a systematic review and meta-analysis of test-negative design case-control studies. J Infect. 2017;75(5):381–94.CrossRefGoogle Scholar
  30. 30.
    Falsey AR, McElhaney JE. Influenza burden in frail elderly. Lancet Respir Med. 2018;6(1):e2.CrossRefGoogle Scholar
  31. 31.
    Franceschi C, Capri M, Monti D, Giunta S, Olivieri F, Sevini F, et al. Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev. 2007;128(1):92–105.CrossRefGoogle Scholar
  32. 32.
    Larbi A, Franceschi C, Mazzatti D, Solana R, Wikby A, Pawelec G. Aging of the immune system as a prognostic factor for human longevity. Physiology (Bethesda). 2008;23:64–74.Google Scholar
  33. 33.
    Murasko DM, Bernstein ED, Gardner EM, Gross P, Munk G, Dran S, et al. Role of humoral and cell-mediated immunity in protection from influenza disease after immunization of healthy elderly. Exp Gerontol. 2002;37(2–3):427–39.CrossRefGoogle Scholar
  34. 34.
    Effros RB. Role of T lymphocyte replicative senescence in vaccine efficacy. Vaccine. 2007;25(4):599–604.CrossRefGoogle Scholar
  35. 35.
    McElhaney JE, Effros RB. Immunosenescence: what does it mean to health outcomes in older adults? Curr Opin Immunol. 2009;21(4):418–24.CrossRefGoogle Scholar
  36. 36.
    McElhaney JE. Prevention of infectious diseases in older adults through immunization: the challenge of the senescent immune response. Expert Rev Vaccines. 2009;8(5):593–606.CrossRefGoogle Scholar
  37. 37.
    McElhaney JE, Ewen C, Zhou X, Kane KP, Xie D, Hager WD, et al. Granzyme B: correlates with protection and enhanced CTL response to influenza vaccination in older adults. Vaccine. 2009;27(18):2418–25.CrossRefGoogle Scholar
  38. 38.
    Shahid Z, Kleppinger A, Gentleman B, Falsey AR, McElhaney JE. Clinical and immunologic predictors of influenza illness among vaccinated older adults. Vaccine. 2010;28(38):6145–51.CrossRefGoogle Scholar
  39. 39.
    Merani S, Kuchel GA, Kleppinger A, McElhaney JE. Influenza vaccine-mediated protection in older adults: impact of influenza infection, cytomegalovirus serostatus and vaccine dosage. Exp Gerontol. 2018;107:116–25.CrossRefGoogle Scholar
  40. 40.
    Berger A. Th1 and Th2 responses: what are they? BMJ. 2000;321(7258):424.CrossRefGoogle Scholar
  41. 41.
    Skowronski DM, Hottes TS, McElhaney JE, Janjua NZ, Sabaiduc S, Chan T, et al. Immuno-epidemiologic correlates of pandemic H1N1 surveillance observations: higher antibody and lower cell-mediated immune responses with advanced age. J Infect Dis. 2011;203(2):158–67.CrossRefGoogle Scholar
  42. 42.
    Skowronski DM, Chambers C, Sabaiduc S, Janjua NZ, Li G, Petric M, et al. Pre- and postpandemic estimates of 2009 pandemic influenza A(H1N1) seroprotection to inform surveillance-based incidence, by age, during the 2013-2014 epidemic in Canada. J Infect Dis. 2015;211(1):109–14.CrossRefGoogle Scholar
  43. 43.
    Goronzy JJ, Fulbright JW, Crowson CS, Poland GA, O’Fallon WM, Weyand CM. Value of immunological markers in predicting responsiveness to influenza vaccination in elderly individuals. J Virol. 2001;75(24):12182–7.CrossRefGoogle Scholar
  44. 44.
    Saurwein-Teissl M, Lung TL, Marx F, Gschosser C, Asch E, Blasko I, et al. Lack of antibody production following immunization in old age: association with CD8(+)CD28(-) T cell clonal expansions and an imbalance in the production of Th1 and Th2 cytokines. J Immunol. 2002;168(11):5893–9.CrossRefGoogle Scholar
  45. 45.
    Mosterin Hopping A, McElhaney J, Fonville JM, Powers DC, Beyer WEP, Smith DJ. The confounded effects of age and exposure history in response to influenza vaccination. Vaccine. 2016;34(4):540–6.CrossRefGoogle Scholar
  46. 46.
    McElhaney JE, Xie D, Hager WD, Barry MB, Wang Y, Kleppinger A, et al. T cell responses are better correlates of vaccine protection in the elderly. J Immunol. 2006;176(10):6333–9.CrossRefGoogle Scholar
  47. 47.
    DiazGranados CA, Dunning AJ, Kimmel M, Kirby D, Treanor J, Collins A, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. 2014;371(7):635–45.CrossRefGoogle Scholar
  48. 48.
    Wilkinson K, Wei Y, Szwajcer A, Rabbani R, Zarychanski R, Abou-Setta AM, et al. Efficacy and safety of high-dose influenza vaccine in elderly adults: a systematic review and meta-analysis. Vaccine. 2017;35(21):2775–80.CrossRefGoogle Scholar
  49. 49.
    Izurieta HS, Thadani N, Shay DK, Lu Y, Maurer A, Foppa IM, et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis. Lancet Infect Dis. 2015;15(3):293–300.CrossRefGoogle Scholar
  50. 50.
    Shay DK, Chillarige Y, Kelman J, Forshee RA, Foppa IM, Wernecke M, et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccines among US medicare beneficiaries in preventing postinfluenza deaths during 2012-2013 and 2013-2014. J Infect Dis. 2017;215(4):510–7.CrossRefGoogle Scholar
  51. 51.
    Young-Xu Y, Van Aalst R, Mahmud SM, Rothman KJ, Thornton Snider J, Westreich D, et al. Relative vaccine effectiveness of high-dose versus standard-dose influenza vaccines among veterans health administration patients. J Infect Dis. 2018;217(11):1718–27.CrossRefGoogle Scholar
  52. 52.
    Gravenstein S, Davidson HE, Taljaard M, Ogarek J, Gozalo P, Han L, et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccination on numbers of US nursing home residents admitted to hospital: a cluster-randomised trial. Lancet Respir Med. 2017;5(9):738–46.CrossRefGoogle Scholar
  53. 53.
    Becker DL, Chit A, DiazGranados CA, Maschio M, Yau E, Drummond M. High-dose inactivated influenza vaccine is associated with cost savings and better outcomes compared to standard-dose inactivated influenza vaccine in Canadian seniors. Hum Vaccin Immunother. 2016;12(12):3036–42.CrossRefGoogle Scholar
  54. 54.
    Chit A, Becker DL, DiazGranados CA, Maschio M, Yau E, Drummond M. Cost-effectiveness of high-dose versus standard-dose inactivated influenza vaccine in adults aged 65 years and older: an economic evaluation of data from a randomised controlled trial. Lancet Infect Dis. 2015;15(12):1459–66.CrossRefGoogle Scholar
  55. 55.
    Schaffner W, Chen WH, Hopkins RH, Neuzil K. Effective immunization of older adults against seasonal influenza. Am J Med. 2018;131(8):865–73.CrossRefGoogle Scholar
  56. 56.
    Baldo V, Baldovin T, Pellegrini M, Angiolelli G, Majori S, Floreani A, et al. Immunogenicity of three different influenza vaccines against homologous and heterologous strains in nursing home elderly residents. Clin Dev Immunol. 2010;2010:517198.CrossRefGoogle Scholar
  57. 57.
    Banzhoff A, Nacci P, Podda A. A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis. Gerontology. 2003;49(3):177–84.CrossRefGoogle Scholar
  58. 58.
    Camilloni B, Basileo M, Valente S, Nunzi E, Iorio AM. Immunogenicity of intramuscular MF59-adjuvanted and intradermal administered influenza enhanced vaccines in subjects aged over 60: a literature review. Hum Vaccine Immunother. 2015;11(3):553–63.CrossRefGoogle Scholar
  59. 59.
    Domnich A, Arata L, Amicizia D, Puig-Barbera J, Gasparini R, Panatto D. Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: a systematic review and meta-analysis. Vaccine. 2017;35(4):513–20.CrossRefGoogle Scholar
  60. 60.
    Iob A, Brianti G, Zamparo E, Gallo T. Evidence of increased clinical protection of an MF59-adjuvant influenza vaccine compared to a non-adjuvant vaccine among elderly residents of long-term care facilities in Italy. Epidemiol Infect. 2005;133(4):687–93.CrossRefGoogle Scholar
  61. 61.
    Puig-Barbera J, Diez-Domingo J, Varea AB, Chavarri GS, Rodrigo JA, Hoyos SP, et al. Effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly. Vaccine. 2007;25(42):7313–21.CrossRefGoogle Scholar
  62. 62.
    Izikson R, Leffell DJ, Bock SA, Patriarca PA, Post P, Dunkle LM, et al. Randomized comparison of the safety of Flublok((R)) versus licensed inactivated influenza vaccine in healthy, medically stable adults >/= 50 years of age. Vaccine. 2015;33(48):6622–8.CrossRefGoogle Scholar
  63. 63.
    Grohskopf LA, Sokolow LZ, Broder KR, Walter EB, Bresee JS, Fry AM, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices—United States, 2017–18 influenza season. MMWR Recomm Rep. 2017;66(2):1–20.CrossRefGoogle Scholar
  64. 64.
    Dunkle LM, Izikson R, Patriarca P, Goldenthal KL, Muse D, Callahan J, et al. Efficacy of recombinant influenza vaccine in adults 50 years of age or older. N Engl J Med. 2017;376(25):2427–36.CrossRefGoogle Scholar
  65. 65.
    Australian Government, Department of Health Influenza: The Australian immunizations handbook. 10th ed. https://immunisationhandbook.health.gov.au/vaccine-preventable-diseases/influenza-flu. Accessed 24 Oct 2018.
  66. 66.
    European Centre for Disease Prevention and Control: Seasonal Influenza Vaccines 2018. https://ecdc.europa.eu/en/seasonal-influenza/prevention-and-control/seasonal-influenza-vaccines. Accessed 11 May 2018.
  67. 67.
    Government of Canada. Canadian Immunization Guide Chapter on Influenza and Statement on Seasonal Influenza Vaccine for 2018–2019. An Advisory Committee Statement (ACS). National Advisory Committee on Immunization (NACI). https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-statement-seasonal-influenza-vaccine-2018-2019.html#5.22018. Accessed 11 May 2018.
  68. 68.
    European Centre for Disease Prevention and Control. Types of seasons influenza vaccine 2018. https://ecdc.europa.eu/en/seasonal-influenza/prevention-and-control/vaccines/types-of-seasonal-influenza-vaccine. Accessed 11 May 2018.

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  • Melissa K. Andrew
    • 1
    • 2
    Email author
  • Susan K. Bowles
    • 1
    • 2
    • 3
  • Graham Pawelec
    • 4
    • 5
  • Laura Haynes
    • 6
  • George A. Kuchel
    • 6
  • Shelly A. McNeil
    • 2
    • 7
  • Janet E. McElhaney
    • 8
  1. 1.Division of Geriatric Medicine, Department of Medicine (Geriatrics)Dalhousie UniversityHalifaxCanada
  2. 2.Canadian Center for VaccinologyHalifaxCanada
  3. 3.Department of PharmacyNova Scotia Health Authority, Central ZoneHalifaxCanada
  4. 4.Second Department of Internal MedicineUniversity of TübingenTübingenGermany
  5. 5.Health Sciences North Research InstituteSudburyCanada
  6. 6.Center on AgingUniversity of Connecticut School of MedicineFarmingtonUSA
  7. 7.Department of Medicine (Infectious Diseases)Dalhousie UniversityHalifaxCanada
  8. 8.Health Sciences North Research InstituteNorthern Ontario School of MedicineSudburyCanada

Personalised recommendations